The Global Primary Cell Culture Market is expected to grow significantly by 2030, fuelled by breakthroughs in the field of cell biology, regenerative medicine, and the development of personalized ...

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

The global modified release formulations market is set for continued expansion between 2025 and 2035, with its size projected to rise from USD 282.1 billion to approximately USD 524.7 billion, ...

FDA's plan to phase out animal testing may hurt Charles River's revenues. The DCF model suggests that CRL presents an ...

View today's WuXi Biologics stock price and latest 2269 news and analysis. Create real-time notifications to follow any changes in the live stock price.

Discover real-time Lonza Group AG (LZAGF) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.

Cell therapies start from living, biological raw materials that carry inherent variability. Even compared to traditional biologics, cell therapy production comes with additional unknowns and risks.